Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. The German Institute ...
Nearly two years have passed since the FDA approved (on April 29, 2010) sipuleucel-T—a therapeutic cancer vaccine developed and marketed by Dendreon Corp. as Provenge—for the treatment of patients ...
Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment A total of 127 patients ...
A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than ...
177Lu-vipivotide tetraxetan PSMA vs cabazitaxel in metastatic castration-resistant prostate cancer: A real-world analysis using the TriNetX database. Death counts and median overall survival (mOS) in ...
WASHINGTON, March 27 (Reuters) - Data on Dendreon Corp.'s Provenge show the prostate cancer therapy may extend survival, but doubts remain about how well it works, U.S. Food and Drug Administration ...
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results